FDA
-
-
-
-
-
-
-
Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Tra
-
-
-
-
-
-
-
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial Results
-
-
-
-
-
-
-
Piper Sandler Reiterates Overweight Rating on Aligos Therapeutics Inc. (ALGS)
-
-
-
-
-
-
-
Aligos Therapeutics Presents 28-Day Safety, Efficacy and Pharmacokinetic Clinical Data for CAM Drug Candidate ALG-000184, First Clinical Data for NASH Drug Candidate ALG-055009 and Nonclinical Data i
-
326,549 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

